Literature DB >> 15289301

Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Daniel K Broderick1, Chunhui Di, Timothy J Parrett, Yardena R Samuels, Jordan M Cummins, Roger E McLendon, Daniel W Fults, Victor E Velculescu, Darell D Bigner, Hai Yan.   

Abstract

The phosphatidylinositol 3'-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3'-kinase catalytic subunits, were identified in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major "hot spots" located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289301     DOI: 10.1158/0008-5472.CAN-04-1170

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  105 in total

1.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

Authors:  Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson
Journal:  Nat Genet       Date:  2012-06-24       Impact factor: 38.330

4.  PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.

Authors:  Hongbo Chen; Lin Mei; Lanzhen Zhou; Xiaomeng Shen; Caiping Guo; Yi Zheng; Huijun Zhu; Yongqiang Zhu; Laiqiang Huang
Journal:  J Neurooncol       Date:  2010-12-29       Impact factor: 4.130

6.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 7.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

8.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

Review 9.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

10.  Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Authors:  Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.